Holen Sie sich die Stockscreener-App
6.803
3.82%
-0.267
Schlusskurs vom Vortag:
$7.07
Offen:
$7.1
24-Stunden-Volumen:
462.41K
Relative Volume:
0.92
Marktkapitalisierung:
$146.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-4.389
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
-0.58%
1M Leistung:
+9.85%
6M Leistung:
+55.96%
1J Leistung:
+1,111%
1-Tages-Spanne:
$6.69
$7.10
1-Wochen-Bereich:
$6.60
$7.22
52-Wochen-Spanne:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.80 | 151.94M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.80 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.85 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.34 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.15 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Important Notice to Long-Term Shareholders of Corcept - GlobeNewswire
UNCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
UNCY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Unicycive's OLC Address Hyperphosphatemia's Unmet Need With Its 3P Advantage? - RTTNews
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Unicycive Therapeutics Inc. benefit from current market trendsJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru
Why is Unicycive Therapeutics Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-02-19 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4%Should You Buy? - MarketBeat
2026-02-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
RA Capital discloses 9.99% Unicycive (UNCY) stake via warrant-linked preferred - Stock Titan
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Will Unicycive Therapeutics Inc. stock go up in YEAR2025 Trade Ideas & Safe Entry Zone Tips - mfd.ru
UNCY Should I Buy - Intellectia AI
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Octagon discloses 1M Unicycive (UNCY) shares, holding under 5% - Stock Titan
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics: Speculative Biotech Stock Whipsaws Traders As Wall Street Stays Cautious - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics Doubles Stock Sale Agreement - MSN
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com
UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance of - GlobeNewswire
FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat
Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
2026-01-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Portfolio Shifts: Is VRAX a top pick in the sectorJuly 2025 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon - simplywall.st
Unicycive Therapeutics (NASDAQ:UNCY) Trading 1% HigherShould You Buy? - MarketBeat
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):